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A report on the 2nd Symposium on Alternative Transcript
Diversity, Heidelberg, Germany, 21-23 March 2006. 
Alternative splicing affects many aspects of eukaryotic
biology and is studied by groups with diverse interests.
Geneticists and biochemists have long been interested in
understanding the molecular mechanisms that underlie
changes in splice-site choice, and the role of splicing regula-
tion in particular biological systems. More recently, compu-
tational biologists have entered the field with the goals of
defining the products of genomes and understanding the
role of alternative splicing in genome evolution. Although
their interests broadly overlap, these fields often utilize dis-
tinct languages, and there have been relatively few meetings
dedicated to bringing the two groups together. Exceptions
have been the symposia on alternative transcript diversity
organized by the European Molecular Biology Laboratory-
European Bioinformatics Institute (EMBL-EBI); the second
symposium was held in March in Heidelberg. This meeting
made clear that the interests of these two groups coincide
more than ever, and that combining genomic approaches
with mechanistic analyses is leading to significant new
understanding of splicing regulation.
The combined approach was apparent in the opening talk
given by one of us (B.G.) describing the use of comparative
genomics in analysis of the splicing of the Dscam locus in
Drosophila. This gene is the most complex system of alter-
native splicing yet described. Dscam contains several large
arrays of alternative exons that are used in a mutually exclu-
sive manner where only one exon in each array is spliced
into the Dscam mRNA. The mechanisms that enforce the
mutually exclusive choice in such a large array are obscure.
For one array (exon 6), the comparative sequence analysis
identified conserved features that predict base pairing
between a docking site in the intron upstream of the array
and selector sequences adjacent to each alternative exon.
This finding leads to a unique model for the regulation of
exon 6 splicing, in which mutually exclusive pairing between
the docking sequence and one of the selector sequences
ensures that only one exon 6 variant is included. 
Splice sites and control elements in RNA 
Comparative genomics, specifically identifying conserved
splicing patterns and regulatory elements, was a recurring
theme. Chris Lee (University of California, Los Angeles,
USA) described how major-form alternative exons, those
that are included in more than two-thirds of a gene’s tran-
scripts, are more highly conserved than minor-form exons,
which are included less frequently. Following the evolution
of exons through the mammalian lineage, Lee estimates
that it takes roughly 40 million years for a newly evolved
exon to become functionalized and fixed in a genome. This
suggests that a low level of inclusion allows newly evolved
exons to persist even if deleterious. In this way, the exon
can continue to evolve and, if it gains advantageous fea-
tures, can become a major-form exon. This evolutionary
pathway seems particularly common in exons that show
tissue-specific inclusion. It has been known for some time
that exons that make functionally significant changes to an
mRNA or protein are generally highly conserved across
related species, such as within the mammalian or wider ver-
tebrate lineages. Extending this idea, Peer Bork (EMBL,
Heidelberg, Germany) described searches for exons whose
regulation is conserved across all metazoans. Starting with
a set of defined orthologous genes, his group defined exons
whose variable inclusion is conserved across multiple
species. Interestingly, few exons are regulated in all species,
but larger numbers show apparent conserved regulationbetween humans and at least one insect. This is an interest-
ing strategy for identifying splicing events of particular bio-
logical importance, given the conservation of their
regulation over such a large evolutionary distance.
The high degree of conservation of regulated exons can be
used to identify new splicing-regulatory sequences. Interest-
ingly, Lee pointed out that the selection against synonymous
codon changes in alternative exons appears too great to be
explained by the set of known exonic regulatory elements,
indicating that there are potentially many more elements to
be identified. To address this issue, Gil Ast (Tel Aviv Univer-
sity, Tel Aviv, Israel) described a novel strategy for identify-
ing new exonic splicing-regulatory sequences by searching
for dicodons (two consecutive codons) whose synonymous
positions are unusually conserved in alternative exons. Some
of these elements were functionally validated in heterolo-
gous reporter genes, where their effects on splicing were sur-
prisingly variable and depended on their exact location
within an exon. Such analyses, which are being conducted by
several different research groups, will ultimately help to
identify the full spectrum of cis-regulatory elements that
control alternative splicing. This is important both for
understanding mechanisms of regulation and as a predictive
tool in defining alternative exons within genomic sequence.
An important question in defining splice sites is the fidelity
of the splicing reaction. Error rates in splicing have been
difficult to measure in vivo because many mis-spliced tran-
scripts are degraded by the nonsense-mediated mRNA
decay pathway. Mihaela Zavolan (Biozentrum, University of
Basel, Switzerland) and Michael Hiller (University of
Freiburg, Germany) have analyzed a special case in which
spliced products differ by three nucleotides through the use
of tandemly duplicated 3 splice sites, also known as
NAGNAG acceptors. Zavolan described the finding that in
most cases, the upstream AG is preferentially used. In
approximately 25% of these sequences, however, either the
downstream AG or both are used. Hiller described the iden-
tification of single-nucleotide polymorphisms (SNPs) that
affect the relative use of the two AGs in NAGNAG
sequences. These are being used to predict which NAGNAG
sequences in the genome will behave as typical sites to
splice only at the upstream AG, and which will produce
splicing at both positions.
Proteins regulating splicing  
Several talks examined the interdependence of the sequence
elements controlling the inclusion of a particular exon.
Bertrand Séraphin (Centre de Génétique Moléculaire, Gif-
sur-Yvette, France) described how the human homolog of
the yeast snu30 protein, a component of the U1 small
nuclear ribonucleoprotein (snRNP), can bind to the pre-
mRNA and affect 5 splice-site choice. Interestingly, human
snu30 is not stoichiometrically associated with the U1
snRNP and is not apparently required for all splicing events,
making it a possible point of regulation for splice-site choice.
Séraphin also described the coordination of the U5 and U6
snRNPs in determining the site of 5 splice-site cleavage and
the role of another splicing factor, the Res protein, in this
selection. Looking at the other end of the intron, Angela
Krämer (University of Geneva, Switzerland) described
extensive studies of the protein SF1, which recognizes the
branchpoint and is required for splicing in yeast. Interest-
ingly, in mammals this protein is not required for all splicing
events, but is needed for certain alternatively spliced exons.
In this case, the requirement for SF1 may be affected by how
well the splicing factor U2AF binds to the 3 splice site. An
RNA interference (RNAi) screen in Drosophila described by
one of us (B.G.) has also identified a number of spliceosome
components as effectors of alternative splicing. Thus, the
role of ostensibly constitutive splicing factors in splicing reg-
ulation was another recurring theme of the meeting. 
Goran Akusjarvi (University of Uppsala, Sweden) described
his group’s recent studies of splicing regulation during
adenovirus infection, which have uncovered a highly specific
regulatory protein. In the viral IIIa gene they discovered a
3 splice site that is active late in viral infection and is not
dependent on the standard spliceosome component U2AF.
In biochemical experiments, they identified the viral protein
L4-33K as the activator of this splice site. L4-33K has an
interesting domain structure that includes the arginine-
serine repeats required for splicing activation. Studies of this
protein should yield important information on how 3 splice
sites are chosen by the spliceosome.
Also apparent is a wave of interest in understanding alterna-
tive splicing on a genome-wide level. Krämer and Javier
Caceres (MRC Human Genetics Unit, Edinburgh, UK) both
used a crosslinking and immunoprecipitation (CLIP) proce-
dure developed in Robert Darnell’s laboratory to identify
large sets of in vivo binding sites for the splicing factors SF1
and SF2/ASF, respectively. DNA microarrays are also
becoming more widely used to characterize alternative splic-
ing throughout the genome, as reported by several groups. A
powerful approach is to examine splicing changes after RNAi
knockdown of particular splicing factors. For example,
Donald Rio (University of California, Berkeley, USA)
described his laboratory’s use of genome-wide splice-junc-
tion arrays to identify exons that are regulated by four
Drosophila heterogeneous nuclear ribonucleoprotein
(hnRNP) family proteins. This was coupled with standard
DNA array analysis of the RNA composition of the pre-mes-
senger RNPs containing these factors. Using this combined
approach, Rio showed that these related Drosophila proteins
each bind distinct, but partially overlapping, sets of tran-
scripts and regulate the splicing of different sets of exons. In
addition to their importance for understanding these specific
regulators, these results constitute very exciting progress in
global splicing analysis. 
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other splicing factors. Two groups presented work showing
that homologs within a family of splicing factors can regulate
the expression of one another. Albrecht Bindereif (University
of Giessen, Germany) described the properties of hnRNP L
and its homolog the L-like protein. HnRNP L targets CA-rich
elements that can act as splicing enhancers or silencers
depending on their location in introns or exons, respectively.
Bindereif and colleagues have identified the L-like protein as
a target of L and vice versa, where RNAi knockdown of one
protein leads to an increase in the other. Similarly, one of us
(D.B.) presented analyses of the regulation of the neuronal
polypyrimidine tract binding protein (nPTB) by its more
widely expressed homolog PTB. This regulation is not simply
due to the regulation of nPTB splicing, but also to regulation
of the translation of nPTB mRNA. This mRNA is present in
most cells, but the protein is only found in certain cell types,
most notably neurons. The tissue specificity of protein
expression apparently results from the repression of nPTB
mRNA translation by PTB in many cell types and, in muscle
cells, by microRNAs. It is likely that these systems of cross
regulation are just the initial observations of a large network
of genetic interactions between splicing factors.
Splicing and human disease 
Another area where progress is particularly evident is in
understanding the role of splicing in human disease and in
applying this understanding to new therapeutic approaches.
Tito Baralle (International Center for Genetic Engineering
and Biotechnology, Trieste, Italy) described how the effect of
mutations in splicing regulatory elements is dependent on
genetic background. His team has found that because alter-
native exons are frequently controlled by multiple elements,
mutations in one regulatory sequence may be silent on their
own, but can make an exon more dependent on other ele-
ments. The complexity of this interplay was further high-
lighted by Cyril Bourgeois (Institut de Génétique et de
Biologie Moléculaire et Cellulaire, Illkirch, France) in regard
to splicing of dystrophin exon 31 and by Joerg Gromoll (Uni-
versity of Münster, Germany) for luteinizing hormone recep-
tor (LHR) exon 10. In each case, exonic mutations destroy or
create binding sites for splicing regulators that alter the
splicing of the exon and cause human disease.
This theme was extended further by several speakers who
discussed the link between alternative splicing and tumori-
genesis. Mariano Garcia-Blanco (Duke University, Durham,
USA) described a system that allows the splicing of particu-
lar alternative exons to be visualized in mice, and his group’s
use of this system to explore changes in the splicing of the
fibroblast growth factor receptor FGFR2 during prostate
cancer progression. Adrian Krainer (Cold Spring Harbor
Laboratory, Cold Spring Harbor, USA) described a wide
array of molecular and genomic approaches to show how
overexpression of the splicing regulator SF2/ASF leads to
cell transformation by activating both the Ras/MAP kinase
and mTOR intracellular signaling pathways. Of particular
interest was the identification of SF2/ASF-induced splice
variants of S6 kinase and other components in the mTOR
pathway, some of which have oncogenic activity on their
own. In a complementary talk, Claudia Ghigna (University of
Pavia, Italy) described how skipping of exon 11 of the gene
for the tyrosine kinase receptor Ron in breast and colon
cancer leads to its constitutive activation and to increased
cell mobility and invasiveness. In a satisfying counterpart to
Krainer’s results, Ghigna showed that exon 11 skipping in
these cells resulted from increased expression of SF2/ASF.
Given the role of alternative splicing in a multitude of
human diseases, there is great interest in the possibility of
therapeutic alteration of splicing. Jamal Tazi (University of
Montpellier II, Montpellier, France) presented the results of
high-throughput screens to identify small molecules that can
alter splicing. Molecules identified were shown to alter both
spliceosome assembly and the modification of specific splic-
ing factors. Ryszard Kole (University of North Carolina,
Chapel Hill, USA) discussed his most recent results using
antisense oligonucleotides to alter splicing patterns. He pre-
sented new chemical modifications that improve the target-
ing of oligonucleotides to specific tissues and, importantly,
efficiently change the splicing of a variety of therapeutic
targets, including beta-globin genes carrying thalassemia
mutations, the tumor necrosis factor (TNF) receptor, and
dystrophin, the protein that is defective in muscular dystro-
phy. Dystrophin splicing is a particularly appealing target,
because simply inducing exon skipping clearly yields thera-
peutic benefit. Annemieke Aartsma-Rus (Leiden University,
Leiden, The Netherlands) presented work on this system
that has identified oligonucleotides that strongly alter dys-
trophin splicing in model systems; trials are now under way
in humans. 
Another intensively studied disease where the ability to alter
splicing would clearly have therapeutic benefit is spinal mus-
cular atrophy (SMA). This disease is caused by mutations in
the gene SMN that result in a loss of SMN protein, a ubiqui-
tously expressed protein involved in a process - the assembly
of snRNPs - that is common to all cells. In addition to
describing new results on the mechanism of snRNP assem-
bly by the SMN protein, Utz Fischer (University of
Würzburg, Germany) presented a zebrafish model of SMA.
One unanswered question posed by SMA is why the loss of
SMN leads specifically to motor neuron degeneration. It was
not known whether this specific defect was due to a function
of SMN specific to motor neurons, or whether motor
neurons are simply more dependent than other cells on SMN
for its normal role in snRNP assembly. Fischer described
how knocking down SMN expression in zebrafish did indeed
lead to a motor neuron defect, which could be rescued by the
co-injection of assembled snRNPs. This argues that the
degeneration of the motor neurons is due to their special
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altering splicing in disease genes are aimed at inducing exon
skipping. This is not the case for SMA, where therapies are
needed that will increase the inclusion of exon 7. Julien
Marquis (University of Bern, Switzerland) described several
strategies for accomplishing this using modified U7 snRNPs
targeted to specific sites in the SMN transcript. These
include attaching a splicing enhancer to exon 7 in trans,
weakening exon 8 splicing by masking the branchpoint, and
improving binding to the nonoptimal exon 7 5 splice site by
a mutant U1 snRNA. All of these generated increased splic-
ing in cell culture and are now being tested in vivo.
The range of questions being addressed and the variety of
techniques described at the meeting made clear that the field
of alternative splicing studies is robust and growing (and
daunting to review). Important progress has been made in a
multitude of directions, but the combination of genome-wide
analyses with focused genetic or biochemical assays is
proving to be particularly powerful. The meeting spurred very
useful dialog between these global and more focused views,
and we are looking forward to the next such gathering.
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